Clinigen Group ROE 2024

Clinigen Group Aktienanalyse

What does Clinigen Group do?

The Clinigen Group PLC is a global pharmaceutical company specializing in the provision of rare disease and hard-to-treat disease treatments. The company was founded in 2010 with the aim of quickly and efficiently providing access to life-saving medicines for patients. However, the history of Clinigen Group goes back further. The company has its roots in Besse Medical, an American drug distributor. In 2004, Clinigen acquired Besse Medical, followed by six more distributors in the US and Europe in the following years. These acquisitions formed the foundation for the current business model. The Clinigen Group's business model is based on three pillars. The first pillar is the "Clinigen Specialty Pharmaceuticals" sector, where the company manufactures and distributes life-saving drugs for severely ill patients worldwide. The second pillar is the "Unlicensed Medicines" business, which allows patients access to unlicensed medicines that are urgently needed in specific cases. Clinigen works with pharmaceutical companies and regulatory authorities to provide these medicines within a certain framework. The third pillar is the "Clinical Trials Supply" department, which supports and streamlines clinical studies by providing medicines and services. Overall, Clinigen offers a variety of products and services, all aimed at securing access to life-saving medicines for patients. These include drugs for the treatment of cancer, infections, autoimmune diseases, neurological diseases, and rare diseases. In addition, Clinigen also offers specialized logistics and distribution services to ensure that medicines reach patients quickly and efficiently. Today, Clinigen Group is a global company headquartered in the UK with offices in North America, Europe, and Asia. The company employs over 1,000 people and works with a variety of pharmaceutical companies and regulatory authorities. An important focus is on the development of new treatment options and therapies for rare and hard-to-treat diseases. Overall, Clinigen Group has established itself as an important player in the pharmaceutical and healthcare industry. The company offers a unique business model and a wide range of products and services to secure access to life-saving medicines for patients worldwide. With its focus on innovation and collaboration with other companies and authorities, Clinigen is committed to ensuring that patients receive quick and efficient access to the medicines they need. Clinigen Group ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding Clinigen Group's Return on Equity (ROE)

Clinigen Group's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Clinigen Group's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Clinigen Group's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Clinigen Group’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Clinigen Group stock

What is the ROE (Return on Equity) of Clinigen Group this year?

The ROE of Clinigen Group this year is 0.07 undefined.

How has the Return on Equity (ROE) of Clinigen Group developed compared to the previous year?

The ROE of Clinigen Group has increased by 0% decreased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of Clinigen Group?

A high ROE indicates that Clinigen Group generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of Clinigen Group?

A low ROE can indicate that Clinigen Group is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of Clinigen Group affect the company?

A change in ROE (Return on Equity) of Clinigen Group can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of Clinigen Group?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of Clinigen Group?

Some factors that can influence Clinigen Group's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does Clinigen Group pay?

Over the past 12 months, Clinigen Group paid a dividend of 0.08 GBP . This corresponds to a dividend yield of about 0.82 %. For the coming 12 months, Clinigen Group is expected to pay a dividend of 0.54 GBP.

What is the dividend yield of Clinigen Group?

The current dividend yield of Clinigen Group is 0.82 %.

When does Clinigen Group pay dividends?

Clinigen Group pays a quarterly dividend. This is distributed in the months of April, December, April, January.

How secure is the dividend of Clinigen Group?

Clinigen Group paid dividends every year for the past 14 years.

What is the dividend of Clinigen Group?

For the upcoming 12 months, dividends amounting to 0.54 GBP are expected. This corresponds to a dividend yield of 5.87 %.

In which sector is Clinigen Group located?

Clinigen Group is assigned to the 'Health' sector.

Wann musste ich die Aktien von Clinigen Group kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Clinigen Group from 1/4/2022 amounting to 0.055 GBP, you needed to have the stock in your portfolio before the ex-date on 12/2/2021.

When did Clinigen Group pay the last dividend?

The last dividend was paid out on 1/4/2022.

What was the dividend of Clinigen Group in the year 2023?

In the year 2023, Clinigen Group distributed 0.514 GBP as dividends.

In which currency does Clinigen Group pay out the dividend?

The dividends of Clinigen Group are distributed in GBP.